J Lab Med Qual Assur.  2019 Jun;41(2):65-74. 10.15263/jlmqa.2019.41.2.65.

Annual Report of the Korean Association of External Quality Assessment Service on Transfusion Medicine (2018)

• Lim YA
• Cho HS

• KMID: 2452699
• DOI: http://doi.org/10.15263/jlmqa.2019.41.2.65

Abstract

Herein, we report the results of the 2018 survey on the external quality assessment (EQA) scheme for the Transfusion Medicine Program (TMP) in Korea. The proficiency testing specimens were prepared at Ajou University Hospital and were sent to the participants biannually. The average accuracy rates for ten different test items on the regular survey were as follows: ABO typing, 99.5%-99.8% (N=841); RhD typing, 99.8%-100.0% (N=827); crossmatching, 89.4%-99.6% (N=708); ABO subtyping, 94.2% and 94.4% (N=53); Rh CcEe antigen testing, all 100.0% (N=51); weak D test, 80.9% (N=207) for the first trial and not graded for the second trial; antibody screening, 99.7%-100.0% (N=304); direct antiglobulin test (DAT) using a polyspecific reagent, 98.9%-100.0% (N=264); DAT using an immunoglobulin-G monospecific reagent, all 100.0% (N=66); DAT using a C3d monospecific reagent, 97.0%-100.0% (N=67); antibody identification, 98.4%-100.0% (N=127); and ABO antibody titration, 84.6%-100.0% (N=73). There were approximately 10.5% more participants in the 2018 EQA scheme than that in 2017. Excellent survey results were obtained in the 2018 EQA scheme compared with those in 2017, except for the weak D test. The 2018 EQA scheme for the TMP should be helpful for improving the quality of the participating laboratories.

Keyword

Transfusion medicine; Quality improvement; Laboratory proficiency testing

MeSH Terms

Coombs Test
Korea
Laboratory Proficiency Testing
Mass Screening
Quality Improvement
Thymidine Monophosphate
Transfusion Medicine*
Thymidine Monophosphate